This research, presented at ACC.26, investigated the efficacy of spironolactone compared to placebo in an elderly patient population diagnosed with heart failure with preserved (HFpEF) or mid-range (HFmrEF) ejection fraction.
This research, presented at ACC.26, investigated the efficacy of spironolactone compared to placebo in an elderly patient population diagnosed with heart failure with preserved (HFpEF) or mid-range (HFmrEF) ejection fraction.